Covidien Plc. (COV)

[stocktrademan]

$COV DD Notes ~ http://www.ddnotesmaker.com/COV

bullish chart

background: http://finance.yahoo.com/news/paulson-co-ups-position-covidien-170054591.html

Medtronic combining with Covidien (offshore move)

Each share of Covidien will be exchanged for 0.965 Medtronic shares and $35.19 in cash. The transaction is expected to close in late 2014 or early 2015 and requires regulatory clearances in the United States, the European Union, China, and certain other countries.

The merger is expected to help the companies expand the portfolio of products sold to hospitals. Medtronic will also benefit from lower taxes under the so-called “tax inversion” after it relocates its domicile to Ireland.

In light of the new rules issued by the U.S. Treasury Department aimed at curbing tax inversion deals, Medtronic said it plans to borrow $16 billion to finance its $43 billion takeover instead of using its overseas cash.

$COV recent news/filings

## source: finance.yahoo.com

Fri, 05 Dec 2014 16:38:00 GMT ~ Form 8.1 – Covidien


read full: http://uk.finance.yahoo.com/news/form-8-1-covidien-163800759.html
*********************************************************

Fri, 05 Dec 2014 16:22:00 GMT ~ Form 8.1 - Covidien


read full: http://uk.finance.yahoo.com/news/form-8-1-covidien-162200173.html
*********************************************************

Fri, 05 Dec 2014 16:18:00 GMT ~ Form 8.1 - Covidien


read full: http://uk.finance.yahoo.com/news/form-8-1-covidien-161800233.html
*********************************************************

Fri, 05 Dec 2014 16:11:00 GMT ~ Form 8.1 - Covidien


read full: http://uk.finance.yahoo.com/news/form-8-1-covidien-161100226.html
*********************************************************

Fri, 05 Dec 2014 16:11:00 GMT ~ Form 8.1 - Covidien

[Business Wire] - Covidien:

read full: http://finance.yahoo.com/news/form-8-1-covidien-161100220.html
*********************************************************


$COV charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$COV company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/COV/company-info
Ticker: $COV
OTC Market Place: Not Available
CIK code: 0001385187
Company name: Covidien plc.
Incorporated In: Ireland


$COV share structure

## source: otcmarkets.com

Market Value: $46,944,640,454 a/o Dec 05, 2014
Shares Outstanding: 452,783,955 a/o Nov 21, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$COV extra dd links

Company name: Covidien plc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/COV/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/COV/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=COV+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=COV+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=COV+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/COV/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/COV/news - http://finance.yahoo.com/q/h?s=COV+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/COV/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/COV/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/COV/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/COV/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/COV/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/COV/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/COV/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/COV/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=COV+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/COV
DTCC (dtcc.com): http://search2.dtcc.com/?q=Covidien+plc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Covidien+plc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Covidien+plc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/COV/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/COV
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/COV/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/COV/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/COV/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001385187&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/COV/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/COV/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/COV/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/COV/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=COV&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=COV
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/COV/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=COV+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=COV+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=COV
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=COV
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=COV+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/COV/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=COV+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/COV.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=COV
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/COV/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/COV/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/COV/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/COV/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/COV
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/COV
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/COV:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=COV
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=COV



$COV DD Notes ~ http://www.ddnotesmaker.com/COV

[blackpantherz]

Options still looking good until deal is finalized

[burton60]

Sweet

[TheFinalCD]

wow CONGRTA$ to whoever sold the 98's

COV

[TheFinalCD]

MDT($60.70) TO BUY COV ($72.02)

VALUE $93.22

http://www.marketwatch.com/story/medtronic-to-acquire-covidien-for-429-billion-in-cash-and-stock-2014-06-15?siteId=


http://ih.advfn.com/p.php?pid=nmona&article=62572638&symbol=MDT

[ECole]

Goldman-Sachs-34th-Annual-Global-Healthcare-Conference Updates

remarks worth reading
http://www.earningsimpact.com/Transcript/81983/COV/Covidien-plc----Goldman-Sachs-34th-Annual-Global-Healthcare-Conference

[Enterprising Investor]

Covidien Completes Separation of Pharmaceuticals Business (7/01/13)

DUBLIN--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced it has completed the separation of its Pharmaceuticals business, which is now held by Mallinckrodt plc, a new independent company. Mallinckrodt will begin “regular way” trading on the New York Stock Exchange today under the symbol "MNK."

The distribution of Mallinckrodt ordinary shares occurred on June 28, 2013. In the distribution, Mallinckrodt issued one ordinary share for every eight Covidien ordinary shares held as of the close of business on June 19, 2013, the record date for the distribution.

Covidien announced in December 2011 that it planned to spin-off the Pharmaceuticals business. While both businesses hold industry-leading positions, they have distinctly different business models, sales channels, customers and capital requirements. In addition, their respective innovation pipelines differ substantially in length, regulatory approval requirements, possible risks and potential returns. The spin-off will enable both businesses to pursue their own strategic and operational plans, including setting optimal levels of investment in research and development and creating business-appropriate capital structures.

"We wish our colleagues at Mallinckrodt continued success as they launch a new, independent specialty pharmaceuticals company focused on pain management and medical imaging diagnostics," said José E. Almeida, Covidien Chairman, President and CEO. “Mallinckrodt has strong market positions based on its core strengths in manufacturing and pharmaceutical formulation.”

"Covidien is well positioned to deliver on its strategic initiatives, including broadening innovation focus, aggressively managing its portfolio, capitalizing on emerging markets opportunities and optimizing spending to provide for investments in innovation and growth," said Mr. Almeida. “We are maintaining our long-term financial goals and continue to target top-line growth at or above the markets in which we compete.”

In fiscal 2012, excluding the Pharmaceuticals business, Covidien had annual sales of $9.9 billion, about evenly split between the U.S. and non-U.S. markets. The Medical Devices business segment represented about 80% of the Company’s sales, with Medical Supplies comprising the remainder. The Company holds the number one or number two market position in categories representing approximately 90% of its sales.

Covidien looks to grow sales at or above the rate of the underlying markets and maintains its previously communicated long-term financial goals of mid-single digit sales growth and double-digit adjusted EPS growth over time. The Company plans to leverage its strong cash flow for long-term profitable growth and remains committed to returning at least 50% of its free cash flow to shareholders annually through dividends and share repurchases.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading products in medical devices and supplies. With 2012 revenue of $9.9 billion, Covidien has 38,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

NON-GAAP FINANCIAL MEASURES

This press release contains financial measures, including adjusted earnings per share and free cash flow, which are considered “non-GAAP” financial measures under applicable Securities & Exchange Commission rules and regulations.

These non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with generally accepted accounting principles. The Company’s definition of these non-GAAP measures may differ from similarly titled measures used by others. The Company defines free cash flow as net cash provided by continuing operating activities less capital expenditures.

The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of Covidien’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Covidien's business.

Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.

FORWARD-LOOKING STATEMENTS

Any statements contained in this communication that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the effect of the spin-off of the Company’s Pharmaceuticals business. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or Company actions to differ materially from what is expressed or implied by these statements. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, our ability to effectively introduce and market new products or keep pace with advances in technology, the reimbursement practices of a small number of large public and private insurers, cost-containment efforts of customers, purchasing groups, third-party payors and governmental organizations, intellectual property rights disputes, complex and costly regulation, including healthcare fraud and abuse regulations and the Foreign Corrupt Practices Act, manufacturing or supply chain problems or disruptions, rising commodity costs, recalls or safety alerts and negative publicity relating to Covidien or its products, product liability losses and other litigation liability, divestitures of some of our businesses or product lines, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, competition, risks associated with doing business outside of the United States, foreign currency exchange rates and environmental remediation costs. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the fiscal year ended September 28, 2012, and in subsequent filings with the SEC. We disclaim any obligation to update these forward-looking statements other than as required by law.

Contacts

Covidien
Jacqueline Strayer, 508-261-8305
Senior Vice President
Corporate Communications
[e-mail]
or
Bruce Farmer, 508-452-4372
Vice President
Public Relations
[e-mail]
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
[e-mail]
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
[e-mail]

http://www.businesswire.com/news/home/20130701005067/en/Covidien-Completes-Separation-Pharmaceuticals-Business

[investora2z]

The stock is now down by more than 11% from its highs. This is the trend with most pharmaceutical stocks as the corrective mood in the market has added to the pressure from profit booking. The weakness in Covidien is highlighted by the fact that it is trading below crucial levels and bounces have not sustained so far. Over the years, the stock has done great for the investors with good appreciation from the lows of around $28 made in 2009. The returns have been good during the past one year also, and stock is still up by 16% on a 52 week basis. The correction has reduced the pressure on valuations and now it is trading around 16 times ttm earnings. Over the years the growth has been more uniform and the revenue and net income have grown. However, there has been some tapering off recently. In the last quarter, the sales had grown by about 5%, but the net income had fallen by about 12%. Future success depends on its ability to deliver new devices / drugs from time to time. Medical devices comprise 68% of its sales and hence it is imperative to bring innovative products to support growth in revenues. Even smaller medical device companies are bringing out interesting products like RenalGuard from PLC Systems (PLCSF) which has got several patents from US / Europe. Covidien recently announced good progress in trials of some of its products. Its Kendall SCD system with Vascular Refill Detection Technology was found to be effective in decreasing development of proximal deep vein thrombosis (DVT). Analysts remain positive on the stock with Goldman Sachs (GS) expecting acceleration in sales and earnings from the second half of FY14. The analysts have a consensus buy recommendation on Covidien with the average price target of around $72 (17-18% appreciation).

[Enterprising Investor]

Options Contract Adjustment (6/21/13)

http://www.cboe.com/publish/TTStockSM/13-355.pdf

[Enterprising Investor]

Open Apology to Jim Cramer

You beat me. You apparently recommended COV to your viewers back in December 2011. Based on your comments, the price has moved up 57 percent since then.

[I just hope you are right about the combined value running up to $74]

[Enterprising Investor]

Thanks for sharing.

Jim thinks like the same things I do sometimes. Just glad I was first... again!

Years ago, I contacted his staff regarding ENR. I have owned it since it was spun off from Ralston Purina. By the time I was contacted by his producer to be on be show, ENR had added something like $20 per share and was already in the $80's. I was unable to participate because of the "day job". He told viewers that night ENR was worth $120.

Then the Great Recession began.

[Olmsted]

Cramer is all over this. Price target of $74 for the what is split from one current Covidien share.

Jim Cramer believes this company is about to create immense value with the stroke of a pen.

"And all they're doing is simply splitting into smaller, cleaner, more easily understood pieces," he said.

Cramer is talking about Covidien, a medical device company, that's spinning off its pharma division which will be called Mallinckrodt.

"Ever since December of 2011, I've been telling you that this move would create immense value, and sure enough, in the time since, Covidien has generated a 56% return," Cramer said.

Now that spin-off is imminent - Mallinckrodt is expected to break away completely by the end of the month.

"Covidien shareholders of record as of June 19th will receive one share of Mallinckrodt—the pharma business—for every eight shares of Covidien they own when the spin happens on June 28th," Cramer explained.

And that begs the question – what's an investor to do now?

"My original thesis was that Covidien's terrific medical device business was being dragged down by a not so hot pharma division; the point of the break up was to separate the strength from the weakness," Cramer said.

However, Cramer would not immediately sell Mallinckrodt . "I think you want to hold on to both," he said.

Now make no mistake; just because Cramer advocates holding both doesn't mean he advocates viewing both in the same way.

Looking at Covidien, Cramer thinks the stock could trade at a higher valuation after the split.

"Right now the non-broken up Covidien is a $65.50 stock that's trading at 15.8 times next year's earnings estimates. Once Covidien breaks up, I think the valuation will get a bit of a boost, because it will be a high-quality pure play medical device outfit. If the new Covidien sells for the same multiple as Abbot Labs, which trades at around 16.4 times next year's estimates, then Covidien, post spin off, should trade up to $68," Cramer said.

Going forward, Cramer can see shares marching even higher simply because it's a good company with solid fundamentals.
"The new Covidien will be a medical device company that can really shine. It's expected to post consistent 4 to 6 percent organic revenue growth, with double-digit long-term earnings per share growth, and a steady dividend to boot, supported by $2 billion in annual free cash flow," he said.

Looking at Mallinckrodt, Cramer sees near term gains but also recommends developing a clear exit strategy.

In the near-term Cramer thinks the stock may trade at a higher multiple. "If it simply trades up to the same levels as comparable branded and generic drug plays, then it could be worth $6 per share of Covidien. Of course, since you're only getting one share of Mallinckrodt for every eight shares of Covidien, that means I expect Mallinckrodt's stock could trade to $48."

However, in the long-term Cramer sees challenges." Mallinckrodt is far from being a great drug company," Cramer said. And I don't like the additional generic competition coming for them in 2014.
Therefore, Cramer says "you should be willing to let it go into strength either after the share price hits $48, or once we get to September when their current fiscal year ends, whichever comes first."

http://video.cnbc.com/gallery/?play=1&video=3000175786

[Enterprising Investor]

Covidien Plc. Ordinary Shares (COV)
$ 65.92 +0.93 (1.43%)
Volume: 2,717,501

After Hours
Last Trade Last: $ 66.52 +0.60 (0.91%)

[Enterprising Investor]

JUL $55 Call quoted $10.00/$10.20 (6/13/13)

Open Interest: 7

Last Trade: 6/03/13 (mine)

[Enterprising Investor]

What a difference a day makes!

Bear of the Day: Covidien (COV) - Bear of the Day (6/12/13)

Source : Zacks
Stock : Covidien Plc. Ordinary Shares (Ireland) (COV)
Quote : 64.99 1.47 (2.31%) @ 8:00PM [Actual 6/13/13 Closing Price]

In the wake of its dismal fiscal 2013 second quarter results, analysts covering Covidien PLC (COV), the $30 billion medical products maker, slashed earnings estimates for both this year and next by 17% each.

Not only did net income decline by 10.2% due to higher expenses, the company also warned about future investment-related expenses due to Japanese yen fluctuations that would further drag down their margins.

Plus, they are in the process of selling their Pharmaceuticals division, which is profitable and will create more uncertain expenses during the divestiture process this month.

Here's a visual of the dramatic drop in analysts estimates since the company's April 26 report, after which it slipped to a Zacks #5 Rank (Strong Sell)...

Regulation, Tax, and Cost Headwinds

The medical-technology excise tax of 2.3% has started to weigh on the bottom line from the second quarter of fiscal 2013. The tax will be a part of the SG&A expense and is expected to be approximately $25 million per quarter.

Moreover, increased investment-related expenses related to emerging markets growth is likely to keep margins under pressure going forward. The company's net income from continuing operations dropped 10.2% in the second quarter of fiscal 2013 due to higher expenses, which dampened solid sales growth.

Covidien is slated to spin-off its Pharmaceutical unit at the end of Jun 2013. The Pharma business is performing well on the back of new products and is contributing significantly to the top line. Following its divestment, Covidien will be left with only the Medical Devices and Supplies businesses.

Although the divestment will allow the company to focus on high-
margin surgical products, uncertainty looms over the growth prospects of these two businesses, given the current difficult healthcare environment.

Path of Least Resistance

At $64, COV is trading about $2 below where it was when it earned a Zacks #5 Rank on May 9. After a gap lower to $62 in the aftermath of its last quarterly report, the stock climbed back above $66 but has met steady selling pressure there.

And the whole Medical Products industry group is under pressure with a Zacks Industry Rank of 171 out of 265 industries, with 72 companies including competitor Baxter (BAX).

Trading over 17 times forward estimates, COV looks poised to at least test the $61-62 support area if not lower into the high $50s. Until the earnings estimate story turns around, this one should be hands off for a while.

Kevin Cook is a Senior Stock Strategist with Zacks.com

[Enterprising Investor]

Covidien Announces Effectiveness of Mallinckrodt Form 10 Registration Statement (6/13/13)

Covidien Expects to Complete Separation of Mallinckrodt on June 28, 2013

DUBLIN--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the Securities and Exchange Commission (SEC) has declared effective the Registration Statement on Form 10 filed by Mallinckrodt plc in connection with the separation of the Pharmaceuticals business from Covidien. Covidien expects to complete the distribution of Mallinckrodt ordinary shares after the close of trading on the New York Stock Exchange (NYSE) on June 28, 2013.

On May 23, 2013, Covidien's board of directors approved the separation of Mallinckrodt, and declared a dividend in specie of the Pharmaceuticals business, to be effected by the transfer of the Pharmaceuticals business from Covidien to Mallinckrodt plc and the issuance by Mallinckrodt of ordinary shares directly to Covidien's shareholders (the “distribution”). Covidien shareholders will receive one Mallinckrodt ordinary share for each eight Covidien ordinary shares held as of the close of business on June 19, 2013, the record date for the distribution. The distribution is subject to the conditions that will be set forth in the Separation and Distribution Agreement between Covidien and Mallinckrodt, the form of which has been filed as an exhibit to Mallinckrodt's Registration Statement on Form 10.

There is currently no market for Mallinckrodt ordinary shares. The NYSE has authorized the listing of Mallinckrodt ordinary shares under the symbol "MNK" following the distribution. Mallinckrodt has been advised that trading in its ordinary shares is expected to begin on a "when issued" basis on June 17, 2013, under the symbol "MNK.WI." "When issued" trading of Mallinckrodt ordinary shares will continue until the distribution occurs. Mallinckrodt "when issued" trades will settle after June 28, 2013, with newly issued ordinary shares of Mallinckrodt.

Beginning on June 17, 2013, and continuing through June 28, 2013, Covidien expects that ordinary shares of Covidien will trade in two markets on the NYSE: "regular-way" under the symbol "COV" and in the "ex-distribution" market under the symbol "COV.WI." Covidien shares trading under "COV" will carry the right to receive shares of Mallinckrodt in the distribution. Covidien shares trading under "COV.WI" will not carry the right to receive shares of Mallinckrodt in the distribution.

Covidien shareholders who sell their shares in the "regular-way" market before June 28, 2013, will also be selling their entitlement to receive Mallinckrodt ordinary shares in the distribution. Covidien shareholders are encouraged to consult with their financial advisors regarding the specific consequences of selling Covidien ordinary shares on or before June 28, 2013.

On July 1, 2013, regular-way trading will commence on the NYSE for Mallinckrodt under the symbol "MNK" and will continue for Covidien under the symbol "COV."

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

FORWARD-LOOKING STATEMENTS

Any statements contained in this communication that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the Company’s planned spin-off of its Pharmaceuticals business including the timing and effect of the transaction. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or Company actions to differ materially from what is expressed or implied by these statements. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, our ability to effectively introduce and market new products or keep pace with advances in technology, the reimbursement practices of a small number of large public and private insurers, cost-containment efforts of customers, purchasing groups, third-party payors and governmental organizations, intellectual property rights disputes, complex and costly regulation, including healthcare fraud and abuse regulations and the Foreign Corrupt Practices Act, manufacturing or supply chain problems or disruptions, rising commodity costs, recalls or safety alerts and negative publicity relating to Covidien or its products, product liability losses and other litigation liability, divestitures of some of our businesses or product lines, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, competition, risks associated with doing business outside of the United States, foreign currency exchange rates, environmental remediation costs and unanticipated developments that may prevent, delay, alter the terms of or otherwise negatively affect the planned spin-off. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the fiscal year ended September 28, 2012, and in subsequent filings with the SEC. We disclaim any obligation to update these forward-looking statements other than as required by law.


Contacts
Covidien
Jacqueline Strayer, 508-261-8305
Senior Vice President
Corporate Communications
[e-mail]
or
Bruce Farmer, 508-452-4372
Vice President
Public Relations
[e-mail]
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
[e-mail]
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
[e-mail]

http://www.businesswire.com/news/home/20130613005823/en/Covidien-Announces-Effectiveness-Mallinckrodt-Form-10-Registration

[vpagano]

To clarify, I meant a link to officially how the contract will be treated after the spinoff. I'm thinking about my old NCT 2014s and 2015s (although they are straightforward 1:1 ratio, no adjustment to strike) as I look at the smallish time value priced in the COV LEAPs. Liquidity in my NCT's has almost completely dried up and (as Olmstead has pointed out on Twitter) I may have to exercise at some point to unlock the full value. Just wondering if that would happen here as well.

To your other point, I can imagine such a thing! Was a doozy of a class in grad school and I think it was simply called Options and Derivatives taught by this guy:

http://www1.villanova.edu/villanova/business/facultyresearch/facultydepartment/biodetail.html?mail=[e-mail]&xsl=bio_long

Did you use a version of this book back then?

http://www.amazon.com/Options-Futures-Derivatives-Derivagem-Edition/dp/0136015867/ref=sr_1_8?ie=UTF8&qid=1370885843&sr=8-8&keywords=options+trading+hall

Supposedly, it still is the gold standard and many a trader keeps one at their desk, I had to sell mine to pay some bills but wish I didn't.

Back to valuation points, I would assume in that book they still talked about doing cash flow based valuations right? Industry-relative is great for growth companies but leaves you with systemic market risk (how I feel about some tech right now).

Only reason I mention it is I think that is one rookie mistake people can make. Recently, I was explaining the difference between an asset play and an earnings play. FYI my example was SHLD. Math and financial modeling is the easy part, deciding WHICH valuation technique to use (comp based, metric based, liquidation based, M&A based, DCF, etc.) requires a little experience and nuance most (or most my age and younger out of school) don't pick up initially.

Anywho, good call here EI! Prime for post-spin appreciation.

[Enterprising Investor]

Comparison shopped to find smallest time premium.

[Olmsted]

Those are some inexpensive options you found...

[Enterprising Investor]

COV's valuation has been very stable over the past five years.

COV is currently trading at 16.82 (TTM). The PE (5YA) is 16.05. The industry average is 26.73 and 32.14, respectively.

On a Price/Sales basis, the values are 2.45 (recent quarter) and 2.52 (TTM). Comparable industry values are 4.63 and 7.36.

COV will be revalued once MNK is spun off.

The valuation of MNK would need to be compared to Pharmaceuticals, where the PE (TTM) is 22.33 and the PE (5YA) is 25.43. Pharma has been trading at a 6.99 PSR (TTM).

All of the information listed above should be deemed a starting point in the valuation process.

[Enterprising Investor]

[From the Department of Corrections]

FINA 4327 Speculative Markets covered options, futures and options on futures.

My team and I have been spending a little too much time trying to help reduce future losses in the FHA MIF.

As I told 56Chevy several years ago, I spend very little time on math when it comes to investing these days. However, I will try to do some here. Then we can all compare notes after the spinoff.

[Enterprising Investor]

Quantity detailed in relative, not absolute terms.

I guess I should have written, "Purchased JUL $55 Call at $8.88 per contract on 6/03/13.

Do I know how the options will be treated after the spinoff? You bet! I had a little help almost 30 years ago from a very nice man named Andrew Chen.

http://www.cox.smu.edu/web/andrew-h-chen

Dr. Chen taught FINA 4327 Speculative Markets. Can you imagine spending an entire semester on options, futures and futures on options? My team project involved arbitraging similar commodities like coffee (long) and cocoa (short). Cocoa prices vary widely due to frequent droughts (I suggest reviewing charts to see it yourself). The portfolio turned out to be a winner with an unusually large alpha value. Only one problem - no real money invested.

In any case, spinoffs also tend to produce unexpected results (see COP/PSX).

I also learned a great deal from Dr. John Peavy, III. I read a journal article which was the foundation for the 1985 book he and the late Dr. David Goodman collaborated on entitled Hyperprofits. The article helped me produce stellar results in my portfolio management class up until the Bhopol disaster wiped a great deal of Union Carbide's market value.

What was the concept behind the book? In simplist terms: industry-relative PE ratios.

[vpagano]

Interesting play here EI, nice. Have you valued the pieces after the spinoff?

Mallinckrodt at 10X last year's earnings would be $27.70.

Divide that 8 = $3.46 per current COV share.

Not much unlocked value being taken into account for in any of the outstanding options that's for sure.

I assume you know how the options will be treated after the spinoff. Using your $55 strike as an example, will that then equate into 100 shares of COV and 12.5 shares of Mallinckrodt per contract?

Thanks.

-V

[Enterprising Investor]

Purchased JUL $55 Call at $8.88 on 6/03/13.

[Enterprising Investor]

Covidien to Issue One Mallinckrodt Shares for Each 8 Covidien Shares in Spinoff (5/24/13) [CORRECTION]

By Melodie Warner
Covidien PLC's (COV) board approved the spinoff of its pharmaceuticals business and set an exchange ratio of one Mallinckrodt PLC shares for eight Covidien shares.

Covidien--a maker of operating-room gear, generic drugs and other medical supplies--said it expects the distribution to occur on June 28 for shareholders of record as of June 19.

Trading of Mallinckrodt shares is expected to begin July 1 on the New York Stock Exchange under the symbol MNK.

Covidien has generally seen improved revenue over the past two years on the strength of its medical-devices sales. It had said it intended to spin off its pharmaceuticals business by mid-2013.

In the meantime, Covidien has been bulking up its pharmaceutical product pipeline through acquisitions, such as October's $100 million acquisition of CNS Therapeutics Inc., a developer of treatments for neurological disorders and intractable chronic pain.

Covidien reported last month its second-quarter earnings fell 12% as restructuring costs and other items masked the company's improved sales.

Shares closed Thursday at $65.21 and were inactive premarket. The stock is up 13% so far this year.

Write to Melodie Warner at [e-mail]

[Enterprising Investor]

Covidien to Issue 8 Mallinckrodt Shares for Each Covidien Share in Spinoff (5/24/13)

By Melodie Warner
Covidien PLC's (COV) board approved the spinoff of its pharmaceuticals business and set an exchange ratio of eight Mallinckrodt PLC shares for each Covidien share.

Covidien--a maker of operating-room gear, generic drugs and other medical supplies--said it expects the distribution to occur on June 28 for shareholders of record as of June 19.

Trading of Mallinckrodt shares is expected to begin July 1 on the New York Stock Exchange under the symbol MNK.

Covidien has generally seen improved revenue over the past two years on the strength of its medical-devices sales. It had said it intended to spin off its pharmaceuticals business by mid-2013.

In the meantime, Covidien has been bulking up its pharmaceutical product pipeline through acquisitions, such as October's $100 million acquisition of CNS Therapeutics Inc., a developer of treatments for neurological disorders and intractable chronic pain.

Covidien reported last month its second-quarter earnings fell 12% as restructuring costs and other items masked the company's improved sales.

Shares closed Thursday at $65.21 and were inactive premarket. The stock is up 13% so far this year.

Write to Melodie Warner at [e-mail]

http://online.wsj.com/article/BT-CO-20130524-704103.html?mod=WSJ_qtoverview_wsjlatest

[Penny Roger$]

~ Friday! $COV ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $COV ~ Earnings expected on Friday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=COV&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=COV&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=COV
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=COV#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=COV+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=COV
Finviz: http://finviz.com/quote.ashx?t=COV
~ BusyStock: http://busystock.com/i.php?s=COV&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=COV >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[Penny Roger$]

<<< $COV Links! >>> ~ MAC's Quick DD Links without the charts.




PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/COV


OTC Markets Company Info ~ http://www.otcmarkets.com/stock/COV/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/COV/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/COV/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/COV/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/COV/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/COV/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/COV/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/COV/research


Google Finance Summary ~ http://www.google.com/finance?q=COV
Google Finance News ~ http://www.google.com/finance/company_news?q=COV
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=COV
Google Finance Financials ~ http://www.google.com/finance?q=COV&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=COV
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=COV&histperiod=weekly#


Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=COV+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=COV+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=COV+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=COV
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=COV+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=COV+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/COV
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/COV
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=COV+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=COV+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=COV+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=COV+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=COV+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=COV+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=COV+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=COV+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=COV+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=COV+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=COV+Cash+Flow&annual


FINVIZ ~ http://finviz.com/quote.ashx?t=COV&ty=c&ta=0&p=d


Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=COV
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=COV
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=COV
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=COV
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=COV
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=COV&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260


CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=COV&exchange=US


Barchart Quote ~ http://barchart.com/quotes/stocks/COV?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/COV
Barchart Options Quotes ~ http://barchart.com/options/stocks/COV
Barchart Technical Chart ~ http://barchart.com/charts/stocks/COV&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/COV&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/COV
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=COV
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/COV
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/COV
Barchart News Headlines ~ http://barchart.com/news/stocks/COV
Barchart Profile ~ http://barchart.com/profile//COV
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=COV&view=key_statistics


OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=COV&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=COV&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=COV&MarketTicker=NYSE&Typ=S


Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/COV/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/COV/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/COV/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/COV/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/COV
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/COV/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/COV/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/COV/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/COV/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/COV/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/COV/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=COV&sid=1795093&framed=False


The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=COV


Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=COV


StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=COV&num1=567&cobrand=&mode=stock


StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=COV
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=COV


AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=COV&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8


Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=COV.PK&WTmodLOC=C4-Officers-5


StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=COV®ion=U


Search NASDAQ ~ http://www.nasdaq.com/symbol/COV
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/COV/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/COV/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/COV/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=COV&selected=COV
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=COV&selected=COV
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/COV/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/COV/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/COV/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/COV/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/COV/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/COV/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/COV/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/COV/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/COV/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/COV/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/COV/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/COV/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/COV/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/COV/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=COV&selected=COV
NASDAQ Financials ~ http://www.nasdaq.com/symbol/COV/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/COV/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/COV/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/COV/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/COV/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/COV/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/COV/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/COV/insider-trades/sells


The Motley Fool ~ http://caps.fool.com/Ticker/COV.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/COV/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/COV/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/COV/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/COV/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/COV/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/COV/Statements.aspx?source=icasittab0000009


MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=COV


YCharts ~ http://ycharts.com/companies/COV
YCharts Performance ~ http://ycharts.com/companies/COV/performance
YCharts Dashboard ~ http://ycharts.com/companies/COV/dashboard


InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=COV&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=COV&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=COV&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=COV


Zacks Quote ~ http://www.zacks.com/stock/quote/COV
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=COV
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=COV


Knobias ~ http://knobias.10kwizard.com/files.php?sym=COV


StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=COV


Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/COV/HOT_TOPIC.html


Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=COV&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=COV®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=COV®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=COV®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=COV®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=COV®ion=USA&culture=en-us


CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=COV


TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=COV


OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=COV&searcharea=e&image1.x=0&image1.y=0


Insidercow ~ http://www.insidercow.com/history/company.jsp?company=COV&B1=Search%21


Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=COV
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=COV&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null


YouTube Symbol Search ~ http://www.youtube.com/results?search_query=COV


Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=COV


Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=COV


Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=COV

Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=COV
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=COV

Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=COV

Investorpoint ~ http://www.investorpoint.com/ enter "COV" and click search.

Hotstocked ~ http://www.hotstocked.com/ enter "COV" and click search.

Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=COV

Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=COV

DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=COV

SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=COV

OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=COV

Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "COV" and click search.

http://www.coordinatedlegal.com/SecretaryOfState.html

http://regsho.finra.org/regsho-Index.html

http://www.shortsqueeze.com/?symbol=COV&submit=Short+Quote%99



DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=COV
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=COV
Check those searches for recent COV mentions. If COV is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS



MACDlinks

[DewDiligence]

COV to open R&D center in Shanghai: #msg-67126157.

[Bart Myers]

Deutsche Bank is out with its report today on Covidien (NYSE: COV), raising its PT from $60 to $61.

In a note to clients, Deutsche Bank writes, "All divisions came in better than expected, notably med devices and pharma. Organic growth looks to be around 4%-5%, an improvement off F1Q's 3% rate. Gross and operating margins were once again strong. Quality EPS beat by $0.04. We're raising our Fiscal 2011-12 EPS estimates to reflect the performance in 2Q, favorable FX rates, and operational performance. To reflect the higher EPS estimate, our price target is now $61 (v. $60). Trading at a discount to peers, we see value and rate COV Buy."


Source: http://www.benzinga.com/analyst-ratings/analyst-color/11/04/1028390/update-deutsche-bank-raises-pt-on-covidien-to-61-cov#ixzz1KXr7ZLnC

[burton60]

so how it working out with COV? Iam loving it, and long the best of old TYCO